source
- GSK secures FDA approval for lung-cancer drug Jideytro after $10.6 billion Nuvalent acquisitionGSK received FDA clearance for Jideytro, a therapy for patients with metastatic non‑small cell lung cancer that have ROS1 gene alterations and have already been treated with another targeted drug.…
- FDA approves Nuvalent lung cancer drug shortly after GSK completes $10.6 billion acquisitionThe FDA announced Wednesday that it has approved a lung cancer medicine from Nuvalent, marking a key regulatory milestone for the biotech. The clearance arrived just a week after GlaxoSmithKline c…